We’ve recently been informed of two events, one flowing from the other, both of which I would term as very disturbing in their own way. First, is this NBER Working Paper that concludes that it is likely that Indian pharmaceutical firms differentiate drug quality based on destination of consumption, to the detriment of African countries. Secondly, is the follow up development that the Indian government may be taking legal action against the authors of the above paper. Needless to say – both...
↧